Ken Griffin’s SELLAS Life Sciences SLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $273K | Buy |
+64,641
| New | +$289K | ﹤0.01% | 10681 |
|
|
2025
Q4 | – | Sell |
-194,357
| Closed | -$378K | – | 13957 |
|
|
2025
Q3 | $313K | Buy |
194,357
+109,364
| +129% | +$195K | ﹤0.01% | 10264 |
|
|
2025
Q2 | $186K | Sell |
84,993
-264,512
| -76% | -$406K | ﹤0.01% | 10744 |
|
|
2025
Q1 | $377K | Sell |
349,505
-135,812
| -28% | -$161K | ﹤0.01% | 9086 |
|
|
2024
Q4 | $505K | Buy |
485,317
+437,998
| +926% | +$500K | ﹤0.01% | 8532 |
|
|
2024
Q3 | $59.1K | Buy |
+47,319
| New | +$57.8K | ﹤0.01% | 11724 |
|
|
2024
Q2 | – | Sell |
-19,718
| Closed | -$26.8K | – | 15295 |
|
|
2024
Q1 | $19.9K | Buy |
+19,718
| New | +$16.6K | ﹤0.01% | 13019 |
|
|
2023
Q3 | – | Sell |
-3,162
| Closed | -$4.99K | – | 15040 |
|
|
2023
Q2 | $4.96K | Buy |
+3,162
| New | +$5.08K | ﹤0.01% | 13549 |
|
|
2023
Q1 | – | Sell |
-3,375
| Closed | -$8.35K | – | 15448 |
|
|
2022
Q4 | $7.96K | Sell |
3,375
-104,185
| -97% | -$292K | ﹤0.01% | 13780 |
|
|
2022
Q3 | $217K | Buy |
107,560
+69,921
| +186% | +$193K | ﹤0.01% | 10252 |
|
|
2022
Q2 | $84K | Buy |
37,639
+24,269
| +182% | +$71.1K | ﹤0.01% | 11563 |
|
|
2022
Q1 | $89K | Sell |
13,370
-27,473
| -67% | -$161K | ﹤0.01% | 12393 |
|
|
2021
Q4 | $226K | Sell |
40,843
-1,646
| -4% | -$12.5K | ﹤0.01% | 11602 |
|
|
2021
Q3 | $389K | Buy |
42,489
+27,658
| +186% | +$257K | ﹤0.01% | 10478 |
|
|
2021
Q2 | $165K | Sell |
14,831
-9,568
| -39% | -$93.4K | ﹤0.01% | 12396 |
|
|
2021
Q1 | $208K | Buy |
+24,399
| New | +$200K | ﹤0.01% | 11619 |
|
|
2020
Q2 | – | Sell |
-19,452
| Closed | -$34K | – | 10444 |
|
|
2020
Q1 | $34K | Buy |
+19,452
| New | +$50.1K | ﹤0.01% | 9158 |
|
|
2019
Q3 | – | Sell |
-5,049
| Closed | -$28K | – | 9707 |
|
|
2019
Q2 | $28K | Buy |
+5,049
| New | +$179K | ﹤0.01% | 8886 |
|
|
2019
Q1 | – | Sell |
-340
| Closed | -$21K | – | 9823 |
|
|
2018
Q4 | $21K | Buy |
+340
| New | +$26.3K | ﹤0.01% | 8735 |
|
|
2018
Q1 | – | Sell |
-45
| Closed | -$18K | – | 8733 |
|
|
2017
Q4 | $18K | Buy |
45
+26
| +137% | +$12.6K | ﹤0.01% | 7844 |
|
|
2017
Q3 | $10K | Sell |
19
-43
| -69% | -$28.4K | ﹤0.01% | 7437 |
|
|
2017
Q2 | $54K | Sell |
62
-46
| -43% | -$40K | ﹤0.01% | 7075 |
|
|
2017
Q1 | $99K | Buy |
108
+71
| +192% | +$118K | ﹤0.01% | 6868 |
|
|
2016
Q4 | $108K | Buy |
+37
| New | +$215K | ﹤0.01% | 6641 |
|
Other funds holding SLS
VCM
VPM
VFT
Ken Griffin's SLS Position: Q1 2026 in Review
Ken Griffin opened a new position in SELLAS Life Sciences (SLS) in Q1 2026: 64,641 shares worth $273K. The stake represents ﹤0.01% of the portfolio and ranks #10681 among its holdings. This is a return to the name: Ken Griffin previously reported a position in SLS as recently as Q3 2025.
Ken Griffin first reported a position in SLS in Q4 2016 and has held it in 24 quarters since. The position peaked at $505K in Q4 2024. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.
- Ken Griffin held 64,641 shares of SELLAS Life Sciences worth $273K as of Q1 2026.
- SELLAS Life Sciences was a new Ken Griffin position in Q1 2026.
- SELLAS Life Sciences made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #10681 holding.
- Ken Griffin first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 24 quarters since.
- Ken Griffin's SELLAS Life Sciences position peaked at $505K in Q4 2024.
- 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.